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The multidisciplinary “New Millennium Indian Technology Leadership Initiative” Arthritis Project was undertaken to validate
Ayurvedic medicines. Herbal formulations in popular use were selected by expert consensus and standardized using modern tools.
Our clinical strategy evolved from simple exploratory evaluations to better powered statistically designed drug trials. The results of
the ﬁrst drug trial are presented here. Five oral formulations (coded A, B, C, D and E), with a common base of Zingiber oﬃcinale
and Tinospora cordifolia with a maximum of four plant extracts, were evaluated; with placebo and glucosamine as controls. 245
patients suﬀering from symptomatic OA knees were randomized into seven arms (35 patients per arm) of a double blind, parallel
eﬃcacy, multicentric trial of sixteen weeks duration. The groups matched well at baseline. There were no diﬀerences for patient
withdrawals (17.5%) or adverse events (AE) of mild nature. Intention-to-treat eﬃcacy analysis, demonstrated no signiﬁcant
diﬀerences (P<. 05) for pain (weight bearing) and WOMAC questionnaire (knee function); placebo response was high. Based
on better pain relief, signiﬁcant (P<. 05) least analgesic consumption and improved knee status, “C” formulation was selected
for further development. Controlled exploratory drug trials with multiple treatment arms may be used to economically evaluate
several candidate standardized formulations.
1.Introduction
Ayurveda, a holistic ethnic medicinal system [1], is in
practice in India and Sri Lanka since the prebiblical era
[2] and has contributed to discovery and development of
natural product drug [3]. The traditional system advocates
predominantly life style (includes diet) approach to good
health and disease prevention. When treating a disease,
herbal mineral formulations are added to the latter approach
after assessing an individual’s constitution traits (called
prakriti in Ayurveda) [2]. Undoubtedly, the traditional
approach is predominantly individual and patient centric
conforming to the basic principle of “no two individuals
are alike.” Unlike a reductionist approach to strike the bull’s
eye (modern medicine), Ayurvedic treatment attempts to
correct several factors implicated in causing the disease
(called samprapti in Ayurveda). The system advocates a
“soil more important than the seed” approach. Though
therapeutic managements may diﬀer, Ayurvedic physicians
often use certain treatment modalities (e.g., the well-known
detoxiﬁcation technique called panchkarma in Ayurveda)
and drugs in a uniform manner to treat diﬀerent disorders.
Chronic arthritis, irrespective of its etiology or clinical pro-
ﬁle, is also one such disorder. Therefore, it may be reasonable
to evaluate Ayurvedic drugs per se for a more general
therapeutic use. But this would entail systematic validation2 Evidence-Based Complementary and Alternative Medicine
using contemporary scientiﬁc methods and evidence [4].
Ayurveda has an elaborate disease classiﬁcation system. In
the case of classiﬁcation of rheumatic disorders [5], we
have reported some similarity between modern medicine
and Ayurveda. Recently, a concept of “golden triangle”
between modern science, modern medicine, and traditional
medicine was proposed to promote integrated research and
development [6].
Ayurvedic medicinal plants have demonstrated remark-
able biological eﬀects, especially those of anti-inﬂammatory
and immunomodulatory activities [7–10], that are relevant
and potentially useful to treatment of chronic musculoskele-
tal disorders. We have carried out several controlled drug
trials to demonstrate eﬃcacy and safety of standardized
Ayurvedic drugs containing several plants mentioned in this
paper, for treatment of osteoarthritis (OA) and rheumatoid
arthritis [11–14].
An Ayurvedic segment of the “New Millennium Indian
Technology Leadership Initiative” (NMITLI), a multidisci-
plinary national project, fully sponsored by the Government
of India, was launched in 2002. The principal aim was to
validate standardized Ayurvedic medicines for global use.
Arthritis, diabetes, and hepatitis were selected as the target
disorders. Experienced Ayurvedic physicians were involved
at every step. The candidate drugs were assessed essentially
using the “reverse pharmacology” approach. This approach
gets credence from the historical and experiential long-
term safe use of Ayurvedic medicines over several hundred
years wherein validation of clinical use precedes or goes
hand in hand with the pharmacological and other relevant
mechanism of action studies.
We selected OA knees as the target disorder. The arthritis
team involved a network of seventeen national research insti-
tutions, hospitals with modern medicine, and pharmaceu-
tical industries with a delegation of speciﬁc responsibilities
(Figure 1). To begin with, Ayurveda and related discipline
experts interacted in brain storming sessions to determine
diagnostic and other critical protocol components (outcome
measures and response criteria, in particular) and shortlisted
medicinal plants with a potential to treat OA knees. Dur-
ing the selection process, due emphasis was given to the
most popular traditional and proprietary formulations, in
Ayurvedic clinical practice in India. Though authoritative
literature reviews, scientiﬁc evidence and expert opinions
were given due importance, the team adopted a consensual
approach to ﬁnalize several key selections and procedures
and settle contentious operative issues, if any. Though
based on traditional principles of Ayurvedic pharmacol-
ogy and pharmaceutics, formulations were developed and
standardized using modern science methods. Safety data
from animal studies was submitted to Institutional Ethics
Committee to obtain clearance prior to the clinical drug
trials. In a step-wise clinical approach (from exploratory to
statisticallydesignedlargesamplesizecontrolleddrugtrials),
the formulations were systematically evaluated (for eﬃcacy
and safety) with a view to identify and validate the best
formulation. We present the results of the ﬁrst of a series of
planned drug trial evaluations completed under the auspices
of the NMITLI project.
2. Patients andMethods
This trial was conducted at the Centre for Rheumatic
Diseases (CRD, Pune), Nizam Institute of Medical Sciences
(NIMS, Hyderabad), KEM Hospital and GS Medical Col-
lege (KEM, Mumbai), and Swami Prakashananda Ayurveda
Research Centre (SPARC, Mumbai). The protocol was duly
approved by the institutional ethics committees of the
respective centers. Prior to signing the informed consent,
patients were properly informed and counseled with a
detailed multilingual brochure.
2.1. Design. This was a randomized, double blind, placebo
and oral glucosamine controlled, parallel eﬃcacy, multicen-
tre drug trial study of 16 weeks duration using seven inter-
vention treatment arms. The trial was essentially exploratory
in nature and not statistically designed for sample size nor
powered (for a low Type II error). Patients were examined by
modern medicine physicians (in particular rheumatologists)
and Ayurvedic physicians.
2.2. Ayurvedic Formulations (Tables 1 and 2)
2.2.1. Selection. Classic Ayurvedic text and medicinal plant
experimental data that is published was referred by the
experts to select the most favored candidate plants and
create a medicinal plant inventory. All the selected plants
were well known and documented in classic literature [15]
and described to possess analgesic, anti-inﬂammatory, and
immunomodulation properties and also to promote positive
health. Herbal and mineral formulations possessing such
a combination of preventive and therapeutic eﬀects are
described as Rasayana (immunomodulators and facilitating
regeneration) in Ayurveda and have been widely used by
Ayurvedic physicians since ancient times to promote health
and treat immunoinﬂammatory and degenerative disorders.
Using systems biology approach, the medicinal properties of
selectedplantswerematchedwiththedesiredclinicaleﬃcacy
targets (both from an Ayurvedic and modern medicine
view point) in an activity matrix to select the formula-
tions. The targets included analgesia, anti-inﬂammatory,
chondroprotection, soft tissue healing, antiosteoporosis,
immunomodulation, antilipogenesis, anabolic eﬀect, and
anti-oxidative stress, in order to promote digestion and
normal gut function. One of the fundamental objectives
of Ayurvedic antiarthritis drugs and regimen is to improve
digestion and metabolism [6].
2.2.2. Test Materials. All the raw materials were procured
from known authorized suppliers who provided passport
data in the form of history data sheets. All the botani-
cal drugs including Shunthi (Zingiber oﬃcinale), Guduchi
(Tinospora cordifolia), Amalaki (Emblica oﬃcinale), Ash-
wagandha (Withania somnifera), and Gokshur (Tribulus
terrestris) were identiﬁed and authenticated by Ayurvedic
experts and medicine plant botanists. Routine pharmacog-
nosy and chemo proﬁling with at least one phytochemical
marker (on HPLC technique) was also completed (Table 1)
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Figure 1: NMITLI Arthritis Project: National Institutional Network, steps and responsibilities. ISHS Interdisciplinary School of Health
Sciences, University of Pune; NBRI National Botanical Research Institute, Lucknow; IIIM Indian Institute of Integrated Medicine, Jammu;
ARI Agharkar Research Institute, Pune; IRSHA Interactive Research School for Health Aﬀairs, Pune; ClinicalTrialCentres: CRD Center for
Rheumatic Diseases, Pune; KEM KEM Hospital, Mumbai; SPARC Medical Research Centre, Kasturaba Society (MRC), Mumbai (Formerly
SPARC); AIIMS All India Institute of Medical Sciences, New Delhi; NIMS Nizam Institute of Medical Sciences, Hyderabad; Industry: NR
Natural Remedies, Bangalore; Zandu Pharmaceutical Works, Mumbai; Arya Vaidya Pharmacy, Coimbatore; Arya Vaidya Shala, Kottakal;
Dabur India Ltd, New Delhi; Nicolas Piramal India Ltd. Mumbai.
Voucher samples (Table 1)o fa l lb o t a n i c a lm a t e r i a l sw e r e
deposited in the oﬃcial herbarium of Agharkar Research
Institute,Pune.FiveAyurvedicformulations(Table 2),coded
as A, B, C, D, and E, were used as investigational drugs. Batch
samples of raw material were properly labeled, sealed and
storedinSHS,Pune,foranyfuturereferenceorinvestigation.
After ensuring quality control standards, the raw material
was processed for extraction.
2.2.3. Development, Standardization, and Manufacture.
Based on traditional knowledge and popular use in
clinical practice, Shunthi and Guduchi were ﬁrst selected
and optimized to create a platform of base formulation.
Synergistic ingredients from the plant inventory were added
to create variants (Tables 1 and 2). Aqueous extracts were
prepared using traditional Ayurvedic procedures [16].
Organic solvents were not used. The precise quantity of each
plant extract ingredient in the formulation was guided by
the standard Ayurvedic teaching text [17]a n dﬁ n a l l yﬁ x e d
by Ayurvedic experts.
Overall, the entire process comprised of several pre-
deﬁned milestone deliverables and suitable tests starting
from creating passport data of raw material, identifying
botanical material (pharmacognosy), to ensuring chemi-
cal quality (Spectroscopic and Chromatographic), molec-
ular (DNA Fingerprinting) standardization, stability, and
pharmacopoeia standards of ﬁnished product. Necessary
documentation was maintained for review, records, and
regulatory needs.
The drug trial test material (Ayurvedic formulations,
placebo, and glucosamine) was manufactured as capsules
with uniform weight (approx. 500mg), similar appearance,4 Evidence-Based Complementary and Alternative Medicine
Table 1: Selected description of medicinal plants (Ayurvedic) and their extracts used to treat symptomatic knee osteoarthritis in a
randomized controlled exploratory study.
Common
name
Botanical name
(Family)
Part used (Extract
type)
Voucher
specimen
number∗
Phytomarker
standardization
by HPLC
Shunthi
Zingiber oﬃcinale
Roscoe.
(Zingiberaceae)
Dried Rhizomes
(Powder) R-035 Total Gingerols
Guduchi
Tinospora cordifolia
Miers.
(Menispermaceae)
Dried stem
(Aqueous extract) R-034 Tinosporosides
Amalaki
Emblica oﬃcinalis
Gaertn
(Euphorbiaceae)
Dried fruits
(Aqueous extract) F-033 Total tannins
Galic acid
Ashwagandha
Withania somnifera
Dunal
(Solanaceae)
Dried roots
(Aqueous extract) R-033 Total
Withanolides
Gokshur
Tribulus terrestris
Linn.
(Zygophyllaceae)
Dried fruits
(Aqueous extract) F-030 Total Saponins
∗Voucher specimen deposited in Agharkar Herbarium at Maharashtra Association for the cultivation of science (AHMA), Pune.
Table 2: Drug codes of Ayurvedic formulations along with the daily dosage regimen (of plant extracts) and comparators (placebo and
glucosamine) used to treat symptomatic knee osteoarthritis in a randomized controlled exploratory study.
Number Ingredients with daily dose Code
1 Shunthi 1000mg + Guduchi 220mg D
2 Shunthi 1000mg + Guduchi 220mg + Amalaki 500mg C
3 Shunthi 1000mg + Guduchi 220mg + Ashwagandha 600mg E
4 Shunthi 1000mg + Guduchi 220mg +G o k s h u r216mg A
5 Shunthi 1000mg + Guduchi 220mg + Ashwagandha 600mg + Gokshur 216mg B
6 Placebo (Maize starch) F
7 Glucosamine sulphate G
and smell. Only permitted pharmaceutical grade excipients
were used. Pharmaceutical grade charcoal, and synthetic
ginger essence were used to give uniform appearance and
smell to placebo and glucosamine. The standards were
consistent with the guidelines for botanical drugs on GMP
(Good Manufacturing Practices) and CMC (Chemistry
Manufacture and Control) provided by the US FDA to the
industry [18].The excipients included pharmaceutical grade
maize starch, talc, charcoal and synthetic ginger essence.
The placebo capsules were ﬁlled with maize starch and
were identical in size, shape, color, and odor to those of
the formulations. Tests were also carried out for microbial
load, heavy metals, pesticide residues, and aﬂatoxins as per
standard norms.
2.2.4. Safety and Activity. Animal toxicity studies were car-
ried out at Agharkar Research Institute, Pune, as per OECD
guidelines Serial Number 423 [19]. The acute and subacute
studieswerecompletedpriortotheinitiationofclinicaltrials
while the chronic toxicity studies were completed later. None
of the animal studies demonstrated any obvious toxicity.
In-house data was generated, both in animal and lab
experiments, to support some of the putative properties
and actions of the selected plants. Moderate analgesic and
anti-inﬂammatory activities were demonstrated in acute and
chronic standard animal pharmacology models. As com-
pared to single drugs, multiple plant formulations exhibited
better eﬃcacy to support the contention of a synergistic clin-
ical activity expected from the trial formulations (data not
shown). Human cartilage (procured during knee surgery)
was cultured in an artiﬁcial medium to set up human
OA explants cartilage model which demonstrated beneﬁcial
eﬀects of the candidate plant extracts and formulations on
some of the critical cellular processes (proteoglycan release,
nitric oxide release, aggrecan release, and hyaluronidase
inhibition ) to further support their clinical use [20–22]. The
selectionprocessofcandidatemedicinalplantsinthisproject
appeared to be vindicated by several experimental studies.
2.3. Patient Selection. Patients suﬀering from symptomatic
OA knees were screened for eligibility as per the protocol
in rheumatology outpatient clinics of participating medicalEvidence-Based Complementary and Alternative Medicine 5
institutions and free-of-cost knee arthritis camps carried out
in community settings. The camp methodology was often
used by CRD, Pune, to meet the large enrollment target of
147 eligible patients within the study time frame. Volunteer
patients signed informed consent to enroll in the trial.
2.3.1. Inclusion Criteria. Patients of either gender belonging
to the 40 to 70 years age group; diagnosis of OA knees based
on typical history, clinical examination ﬁndings and classical
radiological ﬁndings, and fulﬁlling the ACR classiﬁcation
criteria [23] except that the lower age limit was reduced
to 40 years; pain visual analogue score (VAS) ≥4c m s
in one or both the knees while performing a weight
bearing activity (e.g., walking, standing, climbing staircase)
during the preceding 24 hours; patients who were ambulant
and required analgesic and/or NSAID (nonsteroidal anti-
inﬂammatory drug, e.g., ibuprofen) for pain relief and/or
not satisﬁed with ongoing analgesic drugs and seeking
ac h a n g e .
2.3.2. Exclusion Criteria. Women who were pregnant, lac-
tating, and having child bearing potential and not follow-
ing adequate contraceptive measures; patients with known
contraindication to any of the investigational products and
medicinal plants; those who had nondegenerative joint
diseases or other joint diseases which would interfere with
the evaluation of OA; patients with severe disabling arthritis
and/or the patient was who incapacitated and bedridden;
those who had history of intra-articular knee injection
(in particular corticosteroids and hyaluronon equivalents)
within the month preceding the study; those who were
ongoing treatment with anticoagulants, hydantoin, lithium,
steroids, methotrexate, and colchicine; those with history of
active peptic ulcer at any time in the preceding six months
or bleeding ulcer at any time in the past; those with evidence
of severe unstable renal, hepatic, hemopoietic, and cardiac
disorder as revealed by history and/or investigations; those
with history of having received any investigational drug
in the previous one month; patients taking antipyretics,
analgesics, tranquilizers, hypnotics, excessive alcohol, or any
other drug which would interfere with pain perception and
need for other drug therapy for OA, except paracetamol
(allowed as a rescue drug during the study period); those
unwilling to come for regular follow-up for the entire
durationofthestudyandanypatientsconsiderednoteligible
according to the investigator’s discretion.
2.3.3. Wash-Out Period. The patients using NSAID prior to
enrolment were entered into a supervised wash-out period.
Standard recommendations (based on plasma half life)
were followed if the NSAID was known and a maximum
of ﬁve days wash-out was carried out if the name of
analgesic/NSAID used by the patient was unknown. All
other pain relieving medications were discontinued but oral
paracetamol (500mg tablet taken 3 to 4 times in a day) was
permitted as a rescue medication on need basis. However,
if the pain became intolerable, the wash-out phase was
terminated prematurely and the patient entered the trial
intervention phase.
2.4. Randomization. Eligible patients were enrolled on “ﬁrst
come ﬁrst serve” basis and assigned a treatment arm
based on a randomization schedule generated by standard
software under the supervision of a senior investigator (B.
Patwardhan) who was not actively associated with the actual
clinical trials. Patients were randomized in a 1:1 ratio in
any of the seven treatment groups. Each centre was assigned
blocks in multiples of seven according to the predetermined
target of “number of patients to be enrolled.”
2.5. Clinical Evaluation [24]. End point evaluation visits
were made at baseline and at weeks 2, 4, 8, 12, and 16.
Active pain (on weight bearing) and WOMAC index were
considered the primary eﬃcacy variables and recorded at
every visit.
2.5.1. Active-Pain VAS. Patients recorded maximum pain
experienced in both the knees separately on a horizontal
10cms VAS (anchored at 0 for absent pain and 10 for
maximum pain) during weight bearing activity.
2.5.2. Western Ontario and McMaster University’s OA Index
Version LK3 (WOMAC) [25]. A validated and modiﬁed
version of WOMAC questionnaire for Indian use [26]w a s
used to assess pain, stiﬀness, and functional ability in the
knees. The version was further translated into several Indian
regional languages by CRD, Pune, and appropriately retested
for content and comprehension (using back translations and
in small independent patient groups) prior to the actual
trial. The pain and stiﬀness domains in the Indian version
are unchanged from the original version. However, several
questions from the physical function “diﬃculty” domain
have been removed and replaced by those relevant to Indian
customs and traditions (especially those who squat and sit
cross legged). Each of the questions in the pain (5 questions),
stiﬀness (2 questions), and physical function diﬃculty (17
questions) domain was scored by the patient in a face to face
interview conducted by a trained trial paramedic into one of
the categorical answers (none = 0, mild = 1, moderate = 2,
severe = 3, extreme = 4). The score of all the answers was
summed (24 questions with a maximum score of 96) up.
Secondary eﬃcacy variables (clinical and laboratory)
were also recorded and included in pain VAS on rest, and
in walking time (time taken to walk a 50 feet ground level
distance), physician and patient global assessment (graded
from asymptomatic to a very severe category) of disease, in
patient’sgradedassessmentofdrugtolerability,changeinthe
knee status on completion of the study as assessed by the
patient (worse = 1, no change = 2, mild improvement = 3,
moderate improvement = 4, marked improvement = 5) ,a n d
paracetamol consumption. A ﬁxed amount of paracetamol
tablets (500mg each tablet) were provided at each visit
accordingtoapredeterminedscalecontainedintheprotocol.
During the predetermined follow up visit, the number
of tablets that were not consumed were withdrawn and
recorded.Asperthescale,areducingamountofparacetamol
wasissuedateachpredetermined follow-upvisit. Laboratory
variables included several serum cytokine and hyaluronic
acid assays.6 Evidence-Based Complementary and Alternative Medicine
An Ayurvedic CRF was also completed by an Ayurvedic
physician (data not presented).
2.6. Treatment. The prescribed dose was two capsules twice
a day to be taken with plain water after meals (lunch and
dinner). The daily dose of glucosamine sulfate was 1000mg
(250mg/capsule). Concomitant medication, if ongoing and
ﬁxed over time, for concurrent illnesses was permitted.
Patients could continue their regular exercise and/or phys-
iotherapy program begun prior to the current trial but
were discouraged from starting any new activity during
the trial duration. Physical therapy and local applications
of pain relieving ointments/gels for OA knees were not
permitted. Patients were not allowed to seek therapy from
any other alternative medicinal system (such as homeopathy,
acupuncture, and acupressure).
2.7. Laboratory Investigations. The focus of investigations
was on safety rather than any eﬃcacy parameter. Routine
laboratory workup was done at baseline and on completion
of the study. Routine workup included hematology (total
and diﬀerential white blood cell count, platelet count,
erythrocyte sedimentation rate by Westergren method),
biochemistry (blood sugar—Fasting), blood urea, serum
creatinine, serum calcium, serum uric acid, serum biliru-
bin, total serum proteins/albumin/globulin, serum amino-
transferases), rheumatoid factor assay, and urinalysis. Rou-
tine EKGs were taken for all patients at entry. X-rays of
knees were taken to conﬁrm diagnosis. However, as per the
protocol, some special laboratory tests such as serum IL-1,
IL-6, and TNF-α and Hyaluronic acid were carried out more
from a research point of view.
2.8. Adverse Events. Patients were speciﬁcally questioned as
per a predetermined list of common symptoms (anorexia,
nausea, vomiting, diarrhea, constipation, dysuria, skin rash,
giddiness, oral mucous ulcers, dyspepsia, and abdominal
discomfort and pain) based on our experiences in clinical
practice. Patients were also encouraged to volunteer infor-
mation that they considered to be adverse events (AE) or
as i d ee ﬀect (SE). Severe and life-threatening AE were to
be investigated, treated, and notiﬁed as per protocol and
GCP guidelines. The investigator recorded opinions on the
causality/relevance of AE/SE in each case.
2.9. Withdrawals. Patients could withdraw voluntarily or at
the discretion of the Investigator. Patients were not replaced
and the new patient who was enrolled was allotted the next
consecutive randomization number. Eﬀorts were made in
each case to identify the reason for a failed follow-up visit
and/or withdrawal.
2.10. Blinding, Monitoring, and Trial Database. Blinded
coded trial material (investigational products) and random-
ization schedules were provided by SHS. As the coordi-
nating center, CRD organized pretrial sessions for protocol
discussion and standardization of clinical procedures. The
clinical coordinator (M. Saluja) from CRD visited other
trial sites at regular intervals to check trial progress and
documents as per the GCP guidelines. An independent
referee was also designated by the CSIR to visit all the trial
sites and carry out a trial audit. After relevant checks, a copy
of coded trial data was submitted to CSIR (Sponsor and
Monitor) and SHS. The trial data was then decoded under
supervision of S. Sarmukaddam (CRD) and B. Patwardhan
(SHS) and kept locked (password protected). One copy of
the locked database was also submitted to CSIR and SHS
prior to carrying out statistical analysis. Trial data entry was
supervised by M. Saluja. Statistical analysis was carried out
by S. Sarmukaddam and his colleagues.
2.11. Statistical Analysis. At baseline, the qualifying knee/
knees were identiﬁed as the signal joint/joints for subsequent
primary eﬃcacy variable analysis. However, each knee was
examined and recorded separately at each visit. Sample
size was not calculated as per any statistical method and
no assumptions were made regarding “eﬀect size.” At least
30 patients were required to complete the trial in each
arm. Eﬃcacy was assessed by an intention-to-treat analysis
with the “last observation carried forward.” Signiﬁcance was
ascertained at P<. 05. Conﬁdence intervals (95%) were
calculated for all means (of variables) and mean change
over time. We compared the mean change from baseline to
completion in each of the intervention arm using ANOVA.
Within group eﬃcacy was evaluated by one sample Student’s
t-test. Chi-square test was done for all categorical outcomes
including the side-eﬀects/adverse events. Standard statistical
software program SPSS version 12.5 was used.
3. Observations andResults
3.1. At Baseline, the Intervention Arms Were Well Matched.
245 patients (176 females among them) were randomized
into seven arms. The ﬂow of participants in the study is
shown in Figure 2. This project trial was begun on 26 April,
2002 (ﬁrst investigator meeting), and the statistical data
analysisreportwassubmittedon31March,2005,overatotal
period of twenty three months.
T h egr o u p sw e r ew e llm a t c h e df o rs ev e ra lb a s e l i n ed e m o -
graphic and other disease measures as shown in Table 3.
Concomitantdisordersrecordedinthestudywerehyper-
tension (50 patients), diabetes (16 patients), hyperlipidemia
(3 patients), ischemic heart disease (3 patients), bronchial
asthma (1patient), and acid peptic disorders (4 patients); the
numbers of patients are shown in parenthesis.
3.2. Eighteen Percent Patients Withdrew from the Study but
None Due to Serious Adverse Events. Forty three patients
withdrew from the study (as per arm: 6 in A, 6 in B, 6 in C,
5i nD ,5i nE ,6i np l a c e b o ,a n d9i nt h eg l u c o s a m i n ea r m ) .
There were no obvious diﬀerences between the reasons for
withdrawal in any of the groups. However, the reasons were
loss to follow-up (15 patients), noncompliance (4 patients),
change in location (5 patients), poor eﬃcacy (8 patients),
and frequent abdominal upsets/diarrhea (5 patients); not
more than 2 patients ever withdrew from any of the
intervention groups for any of the cited reasons. None of the
patients who withdrew, required hospitalization. Though weEvidence-Based Complementary and Alternative Medicine 7
Screening (n = 440)
Randomized (n = 245)
Allocated to treatment (n = 245)
A (35) B (35) C (35) D (35) E (35) F (35) G (35)
Drop out
(6)
Drop out
(6)
Drop out
(6)
Drop out
(6)
Drop out
(5)
Drop out
(5)
Drop out
(9)
Analyzed
(34)
Analyzed
(34)
Analyzed
(34)
Analyzed
(33)
Analyzed
(33)
Analyzed
(33)
Analyzed
(35)
Excluded (n = 195)
Did not meet inclusion criteria (n = 150)
Refused to participate (n = 25)
Otherr easons (n = 20)
Figure 2: Flow of participants in a seven arm (Five Ayurvedic formulations coded A, B, C, D, and E; oral glucosamine coded G, oral placebo
coded F) exploratory drug trial study of patients with symptomatic osteoarthritis knees (see text for details).
Table 3: Demographic and baseline variables of patients (n = 245) by treatment groups: Ayurvedic arms code (A–E), glucosamine (GLU),
and placebo (PLB).
A B C D E PLB GLU
Number 34 33 35 33 34 34 33
Age (years, mean ± SD) 57.5 ± 7.8 56.6 ± 9.4 56.8 ± 8.1 56.2 ± 9.2 56.2 ± 9.5 54 ± 7.7 54.2 ± 8.1
Weight (Kg ± SD) 63.8 ± 11.2 66 ± 13.6 64.3 ± 13.9 63.5 ±10.5 63.8 ± 10.1 65.6 ± 11.0 65.6 ± 11.8
BMI (Mean, ±SD) 28.3 ± 4.6 28.8 ± 7.5 26.9 ± 4.4 27.7 ± 4.8 27.5 ± 4.5 28.1 ± 5.3 27.6 ± 4.4
Duration of disease (years) 3.9 6.8 4.8 5.1 5.4 4.7 5.9
Active-pain VAS 6.5 (1.2) 6.2 (1.2) 6.3 (1.4) 6.2 (1.2) 6.4 (1.3) 6.4 (1.5) 6.5 (1.4)
W-PAINpPain Pain 9.0 (3.0) 8.3 (3.5) 8.0 (3.0) 8.2 (4.0) 9.2 (3.0) 9.0 (3.7) 8.0 (3.4)
W-DIFF 27 (11.7) 27 (12.2) 25.5 (8.9) 25.0 (12.9) 27.0 (12.3) 28.2 (11.7) 26.0 (10.4)
SD: standard deviation; BMI: body mass index; VAS: visual analogue scale; W: WOMAC questionnaire for functional disability index for knee and hip (see
text for details); DIFF: diﬃculty.
did not grade any AE severe, ﬁve patients (including 2 each
from placebo and glucosamine arms) stopped medication
due to frequent abdominal upsets and withdrew from the
study.
3.3. Only Mild Adverse Events Were Reported with Least
Incidence in the C Treatment Arm. None of the patients in
the current study reported serious AE. All AE were mild
and were treated symptomatically. None of the patients with
AE required invasive intervention or an imaging study. The
common AE/SE reported were epigastric discomfort, vague
diﬀuse dull pain in abdomen, anorexia, nausea, diarrhea,
constipation, and episodic skin rash (mostly nonitchy).
Overall,alesserfrequencyofAEseemedtobereportedinthe
“C” arm as compared to other Ayurvedic intervention arms,
glucosamine, and placebo.
3.4. Amongst All the Groups, “C” Formulation Showed the
Best Response in Reducing Pain. There was no statistically
signiﬁcant diﬀerence (at P<. 05) in the mean change from
baseline to completion in active-pain VAS and WOMAC
index between the groups (Table 4). However, the maximum
reduction in pain was demonstrated by the “C” formulation
(Table 4) and this was further demonstrated at every follow-
up evaluation (Figure 3). The latter improvement was fur-
ther supported by an unequivocal demonstration of lesser
consumption (P<. 05) of a number of oral paracetamol
tablets, both during the total study period and the ﬁnal
four weeks (Table 4). We also analyzed the proportion of
patients showing >60% reduction in the active-pain VAS
from baseline to completion and found that the “C” arm
(12 patients) was ahead of the placebo (8 patients) and
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Table 4:Meanchange(percent)inprimaryeﬃcacyvariables,painvisualanaloguescale(VAS)andWOMAC(W)indexscore,andoraltablet
paracetamol (PARA) consumption from baseline at 16 week completion end point in patients (n = 245) by treatment groups: Ayurvedic
arms code (A–E), glucosamine (GLU), and placebo (PLB); intent to treat analysis.
Code ActivePAINVAS W-PAIN W-DIFF PARA 7 PARA-T
A( n = 31) 0.9 (13.5) 2.3 (17.2) 5.0 (16.5) 1.5 (0.6) 2.1 (0.8)
B( n = 33) 1.6 (24) 2.2 (11.6) 6.9 (22.0) 1.3 (0.8) 1.6 (0.9)
C( n = 30) 1.8 (26) 2.5 (26.7) 5.3 (17.6) 0.9 (0.8)∗ 1.3 (1.0)∗
D( n = 29) 1.2 (18.7) 2.3 (12.9) 5.0 (12.4) 1 (0.9) 1.3 (1)
E( n = 29) 1.3 (19.3) 2.5 (25.9) 5.0 (12.1) 1.5 (0.8) 1.9 (0.9)
GLU (n = 29) 1.43 (18.4) 1.5 (14.2) 4.4 (14.2) 1.4 (0.8) 1.8 (1.1)
PLB (n = 27) 1.38 (18.7) 2.9 (28.2) 7.5 (24.3) 1.2 (0.9) 1.5 (1)
N:number; ∗:P<. 05;W:WOMACquestionnaireforfunctionaldisabilityindexforkneeandhip(seetextfordetails);DIFF:diﬃculty;PARA7:meannumber
of oral paracetamol tablets (each 500mg) consumed daily during the last four weeks of study as a rescue analgesic, F value (ANOVA) = 2.3 (P<. 05); PARA
T: mean number of oral paracetamol tablets (each 500mg) consumed daily during the study period as a rescue analgesic, F(ANOVA) = 2.6 (P<. 05).
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Figure 3: Change in painVAS overtime (months) by treatment
group.
status (Section 2) on completion of the study demonstrated
the best improvement in the “C” arm; a RIDIT (relative
to identiﬁed distribution) analysis (Table 5) showed that
the “C” formulation was deﬁnitely better than the placebo
(P = .03) or glucosamine (P = .09). The latter was
interpreted to mean that more than half of the time, a
randomly selected subject from “C” arm was likely to have
a better knee status as compared to a randomly selected
individual from any of the reference groups (placebo and
glucosamine). Though marginal and modest, the “C” arm
consistently showed a better numerical response for several
other secondary eﬃcacy measures ( Section 2)a sc o m p a r e d
to placebo, glucosamine and several other Ayurvedic drug
intervention (data not shown).
The placebo response was found to be unexpectedly
strong, especially with reference to the WOMAC result
(Table 4).
3.5. Routine Laboratory Parameters of Safety Remained
within Normal Range. There were no statistically signiﬁcant
diﬀerences between the groups for routine hematological,
metabolic, renal, and hepatic parameters (data not shown).
Table 5: Comparison of the change in the knee status of patients
of symptomatic knee osteoarthritis treated with Ayurvedic “C”
formulation (found to be most eﬃcacious), placebo, and glu-
cosamine at completion in a seven arm (5 Ayurvedic formulations)
randomized controlled exploratory drug trial using a RIDIT
(relative to identiﬁed distribution) analysis.
Comparison pair Mean RIDIT “Z” P
C versus placebo 0.652 2.185 .029
C versus glucosamine 0.618 1.692 .09
Knee status on study completion scored by patient using categorical
o u t c o m e( s e et e x tf o rd e t a i l s ) .
Though modest and not signiﬁcant, we observed the best
mean change (drop) in serum hyaluronic acid from baseline
to completion in the “C” arm (data not shown). We also
measured selected serum cytokines (IL-6, IL-1, and TNF-α)
in patients belonging to B, C, glucosamine, and placebo
arms, both at baseline and on completion, but could not ﬁnd
ameaningfulchangeoraconsistenttrendfavoringanygroup
(data not shown).
4. Discussion
In this controlled drug trial study comparing several
Ayurvedic formulations (with a common Z. oﬃcinale-T.
cordifolia base) with glucosamine and placebo in the treat-
ment of symptomatic OA knee, we demonstrated a better
clinical eﬃcacy and safe use of “C” Ayurvedic formulation,
albeit not statistically signiﬁcant. This was an exploratory
study intended to identify the best formulations based on
positiveclinicaltrendsforfurtherdevelopment.Importantly,
the “C” formulation reduced pain (Table 5 and Figure 3)
and requirement of rescue analgesic (Table 4) and improved
the patient centered knee status on completion of study
(Table 5). The decrease in the mean pain VAS from 6.3cms
at baseline to 4.4cms on completion in the “C” arm was
clinically meaningful. Though, the incidence of AE and rate
of withdrawal from study did not discriminate between the
intervention arms (Figure 4), the “C” formulation recorded
a comparatively lesser frequency of AE related to abdominal
symptoms.Evidence-Based Complementary and Alternative Medicine 9
ADE Adverse A B C D E F G
ADE (abbr) (n = 35) (n = 35) (n = 35) (n = 35) (n = 35) (n = 35) (n = 35)
Epigastric discomfort Epi discom 6 13 4 3 11 9 7
Diﬀu s e P a i n a b d o m e n P a i n i n a b d 4422244
A n o r e x i a A n o r e x i a 0112111
N a u s e a N a u s e a6453546
V o m i t i n g V o m i t i n g 1100301
D i a r r h o e a D i a r r h o e a 3110221
C o n s t i p a t i o n C o n s t i p a t i o n 1310032
O r a l U l c e r s O r a l U l c e r s 1100110
S k i n R a s h & I t c h i n g R a s h & I t c h i n g 0343361
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Figure 4: Number of adverse event episodes in patients (n = 245) by treatment group: Ayurvedic arms code (A–E), glucosamine (GLU),
and placebo (PLB).
Our mandate in this initial phase of the NMITLI arthritis
project was to identify the most promising formulation
for development and validation (a subsequent phase of the
project). Accordingly, despite several logistic challenges and
an unprecedented trial, we designed a seven arm controlled
study of sixteen weeks duration to evaluate ﬁve Ayurvedic
formulations for their primary pain relief eﬀect. We included
both oral glucosamine and placebo as controls. A large
number of patients were screened (Figure 2), mostly in a
community setting, to select patients of OA with moderately
severe knee pain (Table 3). At least 30 patients in each
intervention arm completed the study. This trial was not
statistically designed nor adequately powered (in order to
reducethechancesofafalsenegativetrialresult).Theclinical
trial phase (ﬁrst patient screened to last patient completed)
was completed in about 15 months. We were expected to
carry out speedy and economical drug trial evaluations.
Though not intended, we now ﬁnd that the current trial
satisﬁes several of the recently developed recommendations
for reporting of trials of herbal interventions [27].
We have earlier reported a strong placebo response in
Ayurvedic drug trials [11–14] and speculated several causes
related to challenging socioeconomics and cultural beliefs in
our community. However, the phenomenon of “regression
to mean” is well known to masquerade as placebo response.
Indians have faith and high expectations from Ayurveda.
Improvement in the WOMAC questionnaire (pain domain)
is reported to be consistent with the pain relief recorded on
VAS [28] but this did not appear to be the case in the current
study (Table 4). WOMAC assesses the functional ability of
the knees. Perhaps the duration of the current drug trial
study was too short to evaluate a meaningful change in
WOMAC. Also, WOMAC response in the current study was
recordedinoneofthesixregionallanguages(English,Hindi,
Marathi, Telugu, Gujarati, Punjabi, and Urdu) and probably
there wasa lack of suﬃcientstandardization between various
language versions and paramedic investigators. We carried
out a separate analysis of data from each of the study centers
but did not ﬁnd any systematic bias (data not shown).
Though we chose Ayurvedic formulations which are
popularly used in clinical practice, we are aware that the
therapy in Ayurveda is holistic and much more complex.
Validation of the latter traditional approach using a ran-
domized controlled drug trial may not be the most appro-
priate method [29]. Since our study aimed at developing
standardized formulation for general global use, we adopted
a diagnosis centric treatment approach similar to what is
practiced in modern medicine. Standardization of Ayurvedic
drugs is an extremely important and challenging step in
the overall clinical validation process and should not deter
investigators to carry out clinical validation studies such
as the current report. The current Ayurvedic formulations
contained relatively lesser ingredients. The current clinical
trialwassupportedbyseveralexpertsandaccreditednational
institutions (Figure 1) to carry out the arduous task of
standardization and other paraclinical studies including
those of animal toxicity which may not be feasible in a
routine pharmaceutical setting. Some collateral work from10 Evidence-Based Complementary and Alternative Medicine
our NMITLI project regarding the likely mechanism of
action of the selected plant formulation ingredients has been
recently published [21, 22].
We selected OA as the target disorder because it is a
common cause of chronic pains, disability, and poor quality
of life in the community [30]. Except for physiotherapy
and exercises, the therapy options for OA in modern
medicine are grossly limited to providing symptomatic relief
using analgesic, including nonsteroidal anti-inﬂammatory
drugs (NSAID), or a joint replacement in the end stage
situation. Patients often self-medicate and consume anal-
gesics and NSAID for prolonged periods and run a risk
of suﬀering from life-threatening drug toxicity (especially
that of gastrointestinal, renal, and cardiovascular system).
Eﬀective management of OA would need drugs to repair and
strengthen cartilage and prevent future damage. We chose
glucosamine in the current study because it is extensively
used to treat OA worldwide and has been demonstrated
to provide both symptomatic pain relief, improve quality
of life, and reduce cartilage damage [31]. But several other
well-designed studies have challenged the therapeutic role
of glucosamine [32, 33]. The large scale NIH trial [32]
demonstrated limited use of oral glucosamine in the treat-
ment of OA. The outcome with glucosamine in the current
study (Tables 4 and 5, Figure 3) was rather disappointing
but this might have been related to the use of a dose that
is currently considered insuﬃcient [34]b u tw a sp o p u l a r l y
prescribed in our scenario at the time of designing this
study.
Although envisaged since long, there is a void in the
development of chondroprotective drugs. An ideal drug
would be one that provides pain relief and chondropro-
tection. We believe that Ayurvedic medicines, especially
those with Rasayana properties as in the current study,
may fulﬁll the requirement of cartilage repair and chon-
droprotection. This proposition and several other hypothe-
ses are being carefully tested in the NMITLI project
before Ayurveda can address some of the unmet needs
in modern medicine [35]. We have recently completed
an appropriately powered and designed drug trial study
of Ayurvedic “C” formulation in the long-term treatment
of OA knees which also includes surrogate measures of
cartilage damage and chondroprotection (not yet pub-
lished).
In conclusion, we have demonstrated a better eﬃcacy
and safety proﬁle of a standardized Ayurvedic formulation
“C” in the symptomatic treatment of OA knees using a
fast track multiple interventional arm exploratory drug
trial controlled for placebo and glucosamine. The latter
was a preliminary phase of a national project (NMITLI)
and formulation “C” was chosen for further development
and validation. Some of the logistic and socioeconomic
issues connected with trials on traditional medicine, espe-
cially in the Indian scenario, are highlighted. The impor-
tance of using validated health assessment instruments
appropriate for regional use such as Indian version of
WOMAC is also emphasized. We also recommend a mul-
tidisciplinary integrated approach to validate traditional
medicines.
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